Investigating Claims involving AIT Therapeutics Inc.
The White Law Group is investigating potential securities claims involving broker-dealers who may have unsuitably recommended AIT Therapeutics Inc. (formerly Advanced Inhalation Therapies) to investors.
AIT Therapeutics Inc. a clinical stage anti-microbial therapeutic company treating respiratory diseases, reportedly raised an aggregate of approximately $10.9 million in gross proceeds through two separate private placements. In addition, the Company completed its previously disclosed reverse merger on January 13, 2017 to become a publicly-traded company, according to a press announcement.
On January 13, 2017, AIT’s subsidiary, Advanced Inhalation Therapies, issued to investors an aggregate of 1,701,616 of its ordinary shares, together with warrants to purchase an aggregate of 3,403,232 ordinary shares, for gross proceeds of approximately $10.2 million before commissions and expenses.
Ladenburg Thalmann & Co. Inc. acted as lead placement agent and Roth Capital Partners acted as co-placement agent in connection with this transaction.
Further, on March, 31, 2017, AIT issued an aggregate of 110,494 shares of its common stock, together with warrants to purchase an aggregate of 220,988 shares of its common stock, through a private placement that resulted in gross proceeds to AIT of approximately $663 thousand, before commissions and expenses. Laidlaw & Company (UK) Ltd. acted as placement agent in connection with this transaction.
The problem with pharmaceutical and biotech investments such as AIT Therapeutics Inc., is that they typically involve a high degree of risk. The research and development process for pharma companies often involves costly and lengthy testing trials that yield specific data. If the expected data or end points are not met, that could be bad news for investors.
Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.
